Botanix Pharmaceuticals (ASX:BOT) will try out its Permetrex drug delivery system in inflammatory rosacea patients after receiving ethics approval for a phase Ib study of two BTX 1702 formulations in its pipeline. The early-stage clinical study will target the pesky problem of papulopustular rosacea, a pimple-like rosacea that inflames skins that often affects women aged … Continue reading Biotech: Pesky pimple-like rosacea to get Botanix’s Permetrex treatment in early study